The Experts below are selected from a list of 93 Experts worldwide ranked by ideXlab platform
Roy E. Pounder - One of the best experts on this subject based on the ideXlab platform.
-
the absorption of bismuth and salicylate from oral doses of pepto bismol bismuth salicylate
Alimentary Pharmacology & Therapeutics, 2007Co-Authors: Chuka U. Nwokolo, P Mistry, Roy E. PounderAbstract:SUMMARY Plasma bismuth and plasma salicylate concentrations were measured before and after three 30-ml oral doses of bismuth salicylate (Pepto-Bismol liquid) in 10 fasting healthy subjects. From 0 to 120 min following the first dose of bismuth salicylate, the plasma bismuth concentration was less than 1 ng/ml. The peak median plasma bismuth concentration was at + 240 min (1.7 ng/ml; range 0.8–5.3 ng/ml). Salicylate appeared in the plasma of all subjects at + 30 min, and it reached a peak at + 120 min (median 61 mg/L; range 46–104 mg/L). The study demonstrates that, despite rapid and substantial absorption of salicylate, there is negligible absorption of bismuth into the bloodstream from standard oral doses of bismuth salicylate.
S Veldhuyzen Van Zanten - One of the best experts on this subject based on the ideXlab platform.
-
Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.
Antimicrobial agents and chemotherapy, 2005Co-Authors: David E. Mahony, Neil Burford, A. Woods, M. D. Eelman, S Veldhuyzen Van ZantenAbstract:Bismuth subsalicylate (BSS), the active ingredient of Pepto-Bismol, has been used for many years to treat various disorders of the gastrointestinal tract. Using mass spectrometry and the agar dilution method, we determined that insoluble BSS interacts with certain dietary components and organic substrates to produce water-soluble products with activity against Clostridium difficile.
Chuka U. Nwokolo - One of the best experts on this subject based on the ideXlab platform.
-
the absorption of bismuth and salicylate from oral doses of pepto bismol bismuth salicylate
Alimentary Pharmacology & Therapeutics, 2007Co-Authors: Chuka U. Nwokolo, P Mistry, Roy E. PounderAbstract:SUMMARY Plasma bismuth and plasma salicylate concentrations were measured before and after three 30-ml oral doses of bismuth salicylate (Pepto-Bismol liquid) in 10 fasting healthy subjects. From 0 to 120 min following the first dose of bismuth salicylate, the plasma bismuth concentration was less than 1 ng/ml. The peak median plasma bismuth concentration was at + 240 min (1.7 ng/ml; range 0.8–5.3 ng/ml). Salicylate appeared in the plasma of all subjects at + 30 min, and it reached a peak at + 120 min (median 61 mg/L; range 46–104 mg/L). The study demonstrates that, despite rapid and substantial absorption of salicylate, there is negligible absorption of bismuth into the bloodstream from standard oral doses of bismuth salicylate.
David E. Mahony - One of the best experts on this subject based on the ideXlab platform.
-
Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.
Antimicrobial agents and chemotherapy, 2005Co-Authors: David E. Mahony, Neil Burford, A. Woods, M. D. Eelman, S Veldhuyzen Van ZantenAbstract:Bismuth subsalicylate (BSS), the active ingredient of Pepto-Bismol, has been used for many years to treat various disorders of the gastrointestinal tract. Using mass spectrometry and the agar dilution method, we determined that insoluble BSS interacts with certain dietary components and organic substrates to produce water-soluble products with activity against Clostridium difficile.
B. R. Midkiff - One of the best experts on this subject based on the ideXlab platform.
-
Double-blind randomized trial of bismuth subsalicylate and clindamycin for treatment of Helicobacter pylori infection.
Scandinavian journal of gastroenterology, 1992Co-Authors: T. U. Westblom, E Madan, M A Subik, D E Duriex, B. R. MidkiffAbstract:We evaluated clindamycin and bismuth subsalicylate (Pepto-Bismol) for treatment of Helicobacter pylori infection. Patients with culture or histology positive for H. pylori were randomized to receive two tablets of bismuth subsalicylate four times daily for 4 weeks or bismuth combined with 2 weeks of 300 mg clindamycin four times daily. Clinical symptoms were recorded before and after treatment by means of visual analog scales. Patients in both treatment arms showed improvement in clinical scores for abdominal pain, heartburn, and gas or bloating. Microbiologic cure was achieved in only 1 of 11 patients treated with bismuth alone and in none of 7 treated with bismuth/clindamycin. Successful eradication of H. pylori may require combination of multiple antibiotics, as recommended at the IXth World Congress of Gastroenterology, or pharmacokinetic modulators such as H2-blockers or omeprazole.